Back

Lipid management in high cardiovascular risk patients without prior myocardial infarction or stroke - preliminary data from the VESALIUS-REAL global burden study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Improving pharmacotherapy in primary prevention Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Queenie Chan

Amgen Ltd, Greater London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Cardiovascular risks of ibuprofen versus naproxen: a target trial emulation
Doctor A. Bech-Drewes (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Lower rate of ischemic events with alirocumab in patients with atherosclerotic cardiovascular disease but without prior acute ischemic events
Professor D. Bhatt (New York City, US)
Abstract Slides Video
Presentation thumbnail
Aspirin for the primary prevention of major adverse cardiovascular events in patients with elevated lipoprotein(a): a meta-analysis
Doctor P. Lee (Bronx, US)
Abstract Slides Video
Presentation thumbnail
Efficacy of inclisiran in patients affected by familial hypercholesterolemia: data from CHOLINET Registry
Doctor C. Cotticelli (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Cardiorenal protective therapy for CKD: Real world data from the Hellenic Cardiorenal Morbidity Snapshots (HECMOS)
Doctor I. Leontsinis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Improving pharmacotherapy in primary prevention
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Global burden of high-risk cardiovascular patients without prior myocardial infarction or stroke: VESALIUS-REAL - preliminary results from Germany
thumbnail
Congress Presentation
Hitting LDL-C goals in high- and very high-risk patients: why oral combination therapy matters
thumbnail
Congress Presentation
Redrawing the map: why we must cross boundaries in lipid management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources